Corporate Overview Statutory Reports Financial Statements 265 Part ‘B’: Associates and joint venture companies Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to joint arrangements (` cr) No. Name of the entity Latest audited Balance Sheet date Shares of associate | joint arrangements held by the Company on the year end Description of significant influence Reason why the associate| joint arrangements are not consolidated Net worth attributable to shareholding as per the latest audited Balance Sheet Accumulated profit | (loss) Profit | (Loss) for the year No. Amount of investment Extent of holding % Considered in consolidation Not considered in consolidation Associate company 1. Valsad Institute of Medical Sciences Ltd March 31, 2024 13,50,000 22.50 50.00% NA 22.48 0.18 0.09 0.09 Joint venture company 1. Rudolf Atul Chemicals Ltd March 31, 2024 29,18,750 6.13 50.00% Refer Note 1 NA 27.09 21.90 9.64 9.64 Joint operation 1. Anaven LLP March 31, 2024 67 50.00% Refer Note 2 NA 36.20 (30.80) (50.93) 50.93 Note 1: By representation on the Board of Directors of the joint venture company, the Company participation in the policy making process. Note 2: This is a jointly controlled entity. .
RkJQdWJsaXNoZXIy MjA2MDI2